Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study

Francis Guillemin1, Cédric Baumann, Jonathan Epstein

  • 1INSERM CIC Epidémiologie Clinique, CHRU de Nancy, Nancy, France.

Neuroepidemiology
|August 10, 2017
PubMed
Abstract

Insights

Late-onset multiple sclerosis (LOMS) indicates a poorer prognosis and faster disability progression compared to adult-onset MS. This finding holds true regardless of the initial disease course, highlighting LOMS as a critical prognostic factor.

Area of Science:

  • Neurology
  • Clinical Epidemiology

Background:

  • Late-onset multiple sclerosis (LOMS), defined as onset at age ≥50 years, often presents with a primary progressive (PP) course, which is associated with severe disability.
  • Understanding the prognostic implications of age at onset, independent of disease course, is crucial for managing LOMS patients.

Purpose of the Study:

  • To evaluate the independent prognostic role of age at multiple sclerosis (MS) onset on disability progression.

Main Methods:

  • A population-based cohort study involving 3,597 patients.
  • Cox regression modeling was used to assess the association between age at onset (adult-onset MS [AOMS] vs. LOMS) and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6.

Main Results:

  • LOMS was diagnosed in 245 patients and was associated with a less frequent relapsing-remitting (RR) disease course compared to AOMS (51.8% vs. 90.8%).
  • LOMS independently predicted a shorter time to reaching EDSS 4 and 6 (HR 2.0 and 2.3, respectively), irrespective of PP course or male gender.
  • The impact of LOMS on disability progression was more pronounced in patients with RR disease than in those with PP disease.

Conclusions:

  • Late-onset MS is a significant independent predictor of poor prognosis and accelerated disability progression.
  • Age at onset is a critical factor in determining long-term outcomes in multiple sclerosis patients.

Related Concept Videos

Longitudinal Research02:20

Longitudinal Research

Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.5K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
267
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
278
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
298
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
761
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
283